Cash, Cash Equivalents and Restricted Cash

9 Months Ended

Sep. 30, 2021

Cash and Cash Equivalents [Abstract]

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts shown in the Condensed Consolidated Statements of Cash Flows:


(in thousands)	As of September 30, 2021		As of December 31, 2020
Cash and cash equivalents available for general corporate purposes	$	66,240	$	210,841
Joint venture cash and cash equivalents	121,295		163,448
Cash and cash equivalents	187,535		374,289
Restricted cash	6,922		77,563
Total cash, cash equivalents and restricted cash	$	194,457	$	451,852

Cash equivalents include short-term, highly liquid investments with maturities of three months or less when acquired. Cash and cash equivalents consist of amounts available for the Company’s general purposes, the Company’s proportionate share of cash held by the Company’s unconsolidated joint ventures and 100% of amounts held by the Company’s consolidated joint ventures. In both cases, cash held by joint ventures is available only for joint venture-related uses, including future distributions to joint venture partners.

Restricted cash primarily includes amounts held as collateral to secure insurance-related contingent obligations, such as insurance claim deductibles, in lieu of letters of credit. As of December 31, 2020, restricted cash also included $69.9 million held to repay the outstanding principal balance of Convertible Notes, as defined in Note 9, which matured and were repaid on June 15, 2021.